双环醇与拉米夫定治疗慢性乙型肝炎的抗病毒和复常肝功能效应的成本-效益分析

Cost-effectiveness Analysis of Anti-HBV and Liver Function Recovery between Bicyclol and Lamivudine in Treating Chronic Hepatitis B.

目的评价双环醇与拉米夫定在治疗慢性乙型肝炎中的抗病毒和复常肝功能的疗效、不良反应、成本-效益.方法将100例慢性乙型肝炎患者随机分成治疗组和对照组,分别予双环醇或拉米夫定.运用药物经济学成本-效益分析方法,对2组方案的复常肝功能和抗病毒效应的疗效及成本进行比较.结果在临床治疗终点的48周末,双环醇组与拉米夫定组的ALT复常率、HBV-DNA阴转率分别为92.0%、82.0%和44.0%、60.0%,2组的差异无显著性意义(p>0.05).双环醇与拉米夫定ALT复常率成本-效益比分别为55.3和70.0;HBV-DNA阴转率的成本-效益比分别为115.7和95.7.结论在疗程结束时,2组的复常肝功能和抗HBV效应基本相似.双环醇治疗慢乙肝的成本-效益比优于拉米夫定.

Objective To compare the clinical efficacy, adverse reactions and the costs - effectiveness between Bicyclol and Lamivudine in treating chronic hepatitis B. Methods One hundred patients with chronic hepatitis B were matched pair divided into treatment group and control group and gave bicyclol and lamivudine respecfly. Their alanine aminotransferase（ALT） recovery and anti - HBV efficacy had been observed. The results were compared by pharmacoeconomic cost-effectiveness analysis. Results At the end 48 week（the point of treatment）, there were no significant difference in the ALT recovery rate and HBV - DNA negative conver- sion rate between two groups. The cost - effectiveness ratios of bicyclol and lamivudine in ALT recovery rate were 55.3 and 70.0 respectively;in HBV - DNA negative conversion rate were 115.7 and 95.7 respectively. Conclusions At the end of treatment, the liver function recovery and anti HBV of two groups were similar. But the cost - effectiveness ratios of bicyclol is superior to that of lamivudine.